Autolus Therapeutics (AUTL) Announces $250M Investment from Blackstone (BX) to Advance CAR T Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Autolus Therapeutics (AUTL) Announces Publication Describing its Controllable CAR T Cell System
November 10, 2021 7:06 AM ESTAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the publication of an article in Nature Scientific Reports describing a controllable CAR T cell system (TetCAR), designed to reversibly dampen the activity of the programmed T cells by the administration of the licensed and widely available antibiotics tetracycline and minocycline.1
Management of toxicities is a critical step in the successful application of programmed cell therapies. TetCAR is one of a number of approaches developed at Autolus that use a pharmacological agent... More
Autolus Therapeutics (AUTL) Deal with Blackstone Overall Positive - Mizuho
November 8, 2021 1:03 PM ESTMizuho Securities analyst Mara Goldstein reiterated a Buy rating and $18.00 price target on Autolus Therapeutics (NASDAQ: AUTL) after catching up with management following today's Blackstone deal.
Goldstein notes the funding model is minimally dilutive to obe-cel's earning potential and the access to capital... More
